WO2005021745A1 - 肝細胞癌に関連する遺伝子 - Google Patents
肝細胞癌に関連する遺伝子 Download PDFInfo
- Publication number
- WO2005021745A1 WO2005021745A1 PCT/JP2004/012425 JP2004012425W WO2005021745A1 WO 2005021745 A1 WO2005021745 A1 WO 2005021745A1 JP 2004012425 W JP2004012425 W JP 2004012425W WO 2005021745 A1 WO2005021745 A1 WO 2005021745A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- cancer
- group
- recurrence
- genes
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to a gene associated with hepatocellular carcinoma, particularly a gene associated with recurrence of hepatocellular carcinoma.
- hepatocellular carcinomas develop from chronic hepatitis due to viral hepatitis.
- the causative viruses are hepatitis C virus and hepatitis B virus.
- Interferon is used as a treatment for hepatitis, but only 30% of cases are effective and are not necessarily sufficient.
- the virus cannot be eliminated, if the progression of the disease state can be suppressed, it will lead to the prevention of cirrhosis and hepatocellular carcinoma. Therefore, it is important to clarify the pathological factors at the molecular level.
- liver cancer 5 years after surgery is 51% nationwide, and it is reported that relapse occurs in about 25% 1 year after hepatectomy, 50% 2 years after, and 80% 5 years after hepatectomy .
- the remaining liver tissue cannot be said to be normal liver tissue, and it is thought that there is already a bud of hepatocellular carcinoma recurrence.
- recurrence risk factors such as tumor maximum diameter, number, portal vein tumor thrombus, preoperative AFP value, intrahepatic metastasis, and presence or absence of cirrhosis are reported.
- Gene expression analysis by DNA microarray is considered to be a powerful method for knowing the prognosis of such cancers.
- An object of the present invention is to provide a gene associated with hepatocellular carcinoma, particularly a gene that predicts recurrence of cancer.
- the present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result of examining gene expression profiles from cases in which hepatocellular carcinoma has recurred and cases in which hepatocellular carcinoma has not recurred, Was successfully identified, and the present invention was completed.
- the present invention is as follows.
- a method for evaluating cancer comprising the following steps:
- the method comprising:
- PSMB8 gene for example, PSMB8 gene, RALGDS gene, GBP1 gene, RPS14 gene, CXCL9 gene, DKFZp564F212 gene, CYP1B1 gene, TNFSF10 gene, NR0B2 gene, MAFB gene
- At least one gene selected from the group consisting of BF530535 gene, MRPL24 gene, QPRT gene, VNN1 gene and IRS2 gene can be used.
- at least one gene selected from the group consisting of PZP gene, MAP3K5 gene, TNFSF14 gene, LMNA gene, CYP1A1 gene and IGFBP3 gene can be used.
- Each gene included in the set can also be used.
- a gene set consisting of VNN1, CXCL9, GBP1, and RALGDS genes, or LMNA gene a gene included in the gene set consisting of the gene, COL1A2 gene and PZP gene can also be used.
- Evaluation of cancer predicts the presence or absence of metastasis or recurrence.
- Examples of the cancer include hepatocellular carcinoma.
- the expression level of the gene is measured by a gene set consisting of the VNN1 gene and the MRPL24 gene, a gene set consisting of the PRODH gene, the LMNA gene and the MAP3K12 gene, a gene set consisting of the VNN1 gene, the CXCL9 gene, the GBP1 gene, and the RALGDS gene.
- Genes are amplified using a combination of primers for amplifying each gene contained in at least one gene set selected from the group consisting of the LMNA gene, LTBP2 gene, COL1A2 gene, and PZP gene. It can be done by doing.
- a primer set comprising at least one combination of primers consisting of the nucleotide sequences represented by SEQ ID NOs: 2n-1 and 2n (n represents an integer of 1 to 114).
- a primer set comprising a combination of primers for amplifying each gene contained in at least one gene set selected from the group consisting of a COL1A2 gene and a PZP gene.
- a cancer evaluation kit comprising any one of the genes shown in Tables 1 to 8.
- Examples of the gene shown above include at least one gene selected from the group consisting of RALGDS gene, GBP1 gene, DKFZp564F212 gene, TNFSF10 gene and QPRT gene.
- the above-mentioned genes include, for example, a gene set consisting of VNN1 gene and MRPL24 gene, a gene set consisting of PRODH gene, LMNA gene and MAP3K12 gene, a gene set consisting of VNN1 gene, CXCL9 gene, GBP1 gene and RALGDS gene.
- the kit of the present invention can include the primer set.
- a gene useful for predicting the recurrence of hepatocellular carcinoma is provided. By analyzing the state of enhanced expression of this gene, cancer can be evaluated. In particular, by using the gene of the present invention, recurrence of hepatocellular carcinoma can be predicted, and the obtained prediction information is useful for a subsequent treatment plan. In addition, using these genes and gene products, it is possible to develop therapeutic methods for preventing recurrence.
- FIG. 1 is a diagram showing a sample phylogenetic tree prepared from all gene expression profiles. Genes were rearranged based on the similarity of expression between samples, and the similarity of expression between all genes rearranged the samples to show a close relationship as a phylogenetic tree.
- the present invention is based on the long-term follow-up clinical data after resection of hepatocellular carcinoma, from the group of patients with poor prognosis (for example, those who relapse within 1 year and die within 2 years) and those with good prognosis ( For example, a gene group that expresses poor prognosis or improves prognosis (e.g., genes involved in promoting recurrence and ).
- the present invention is based on the clinical data, classifying cases of hepatocellular carcinoma type B and cases of hepatocellular carcinoma by causative virus, and prognostic correlation between non-cancerous tissue and cancerous tissue, respectively. Is identified.
- the gene of the present invention analyzes the correlation between the tissue actually collected from a patient and the disease state, in which case, in which disease state, and which gene is examined to find out the correlation between the gene and the disease state. It was clarified.
- test samples are observed in the course of liver cancer surgery and classified into early recurrence and late recurrence groups.
- the early recurrence group means a group of patients who relapse within a certain period after resection and die later.
- the period until the recurrence is not particularly limited, and may be, for example, within one year or within two years.
- the period until death is not particularly limited, but may be, for example, within one year, two years, or three years after recurrence.
- the delayed group refers to a group of cases that have not recurred for a certain period of time (eg, 3 years or more, preferably 4 years or more).
- 51 sge I and sge II hepatocellular carcinoma surgery cases were targeted. This includes 16 cases of hepatocellular carcinoma type B and 35 cases of hepatocellular carcinoma type C. Based on these follow-up clinical data, patients with type B hepatocellular carcinoma Two cases, three cases from type C hepatocellular carcinoma, 2 cases from type B hepatocellular carcinoma, and three cases from type C hepatocellular carcinoma were selected as the recurrence delay group. The following expression profiles were analyzed for the RNAs of non-cancerous and cancerous tissues of these 10 cases. 2.
- Total RNA is extracted from the liver tissues of the groups classified as described above, and the gene expression profiles of each group are compared using a microphone-mouth array. Extraction of total RNA can be performed by using a commercially available reagent (for example, Trizol). The expression profile is detected, for example, using a microarray (Affymetrix).
- a commercially available reagent for example, Trizol
- the expression profile is detected, for example, using a microarray (Affymetrix).
- the present invention can analyze genes that fluctuate in tissues of non-cancerous parts as well as cancerous parts.
- the non-cancerous part refers to a part of the liver tissue that is included during resection of hepatocellular carcinoma and does not include cancer cells.
- the “non-cancerous site” is not necessarily normal liver tissue, but also includes chronic hepatitis (hepatitis B and C) or liver cirrhosis.
- a gene whose expression is upregulated in a non-cancerous part can be analyzed in a group of delayed recurrence of type B hepatocellular carcinoma cases and type C hepatocellular carcinoma cases where most such tissues are present.
- Evaluation of cancer means evaluation of the condition and progress of cancer, and includes predicting the presence or absence of metastasis and recurrence.
- the present invention provides a gene whose expression is promoted or suppressed, particularly in relation to recurrence.
- Recurrence refers to the appearance of new cancerous lesions in the liver after it is determined that treatment for the primary lesion has been completed.
- cDNA is synthesized using commercially available reverse transcriptase with the to 1 RA prepared as described above.
- Commercially available PCR reagents can be used, and PCR conditions may be in accordance with commercially available protocols. For example, after preheating for 95 or 10 minutes, the conditions are 95 ° C for 15 seconds, 60 ° C (or 65 ° C), and 60 seconds for 40 cycles.
- the target internal standard genes include, for example, glyceraldehyde 3-phosphatase dehydrogenase (GAPDH)> 18S ribosomal RNA (18S rRNA), ⁇ -Actin, cyclophilin A, HPRT1 (Hypoxanthine phosphoribosyltransferase 1), B2M (beta-2 microglobulin), Receptors such as ribosomal protein L13a, ribosomal protein L4 and the like can be used, and those skilled in the art can appropriately select them.
- GPDH glyceraldehyde 3-phosphatase dehydrogenase
- 18S rRNA 18S ribosomal RNA
- ⁇ -Actin 18S ribosomal RNA
- cyclophilin A 18S ribosomal RNA
- HPRT1 Hypoxanthine phosphoribosyltransferase 1
- B2M beta-2 microglobul
- the absolute quantification of the expression level is obtained by determining the threshold line at which the calibration curve is optimal, and determining the threshold PCR cycle number and threshold cycle (Ct) value of each sample.
- the relative expression level is expressed by the A Ct value obtained by subtracting the Ct value of the internal standard gene (eg, GAPDH) from the Ct value of the target gene.
- a value calculated by the formula of (2 ( _ ⁇ ) ) can be used.
- Genes were selected from the results of the microarray in the delayed recurrence group and the early recurrence group, and the results of real-time PCR obtained using the above method showed correlation with the time to recurrence among genes that matched the microarray results.
- the gene can be identified, for example, as a non-cancerous site expression enhancing gene.
- genes can be selected depending on experimental conditions at the time of identification, for example, depending on an internal standard gene used, a primer sequence, an annealing temperature, and the like.
- various statistical methods for example,
- Mann-Whitney U test can be used to select genes that correlate with the time to recurrence.
- the full-length sequence of the gene of the present invention can be obtained as follows. That is, it can be retrieved from a DNA database and obtained as known sequence information. Alternatively, it is isolated from a human liver cDNA library by hybridization screening.
- the genes whose expression is enhanced in cases where recurrence was not early are shown in Tables 1 to 4, and the expression is enhanced in cases where recurrence is early. Genes include those shown in Tables 5-8. Table 1: Genes whose expression is upregulated in non-cancerous areas in the delayed recurrence group of B-cell hepatocellular carcinoma cases (24)
- Table 3 Genes whose expression is upregulated in the cancerous part of the group with delayed recurrence in hepatocellular carcinoma type B (137)
- Table 5 Genes that are upregulated in non-cancerous areas in the early recurrence group of type B hepatocellular carcinoma cases (48)
- Table 7 Genes that are upregulated in the cancerous part in the early recurrence group of type B hepatocellular carcinoma cases (75)
- Table 8 Genes that are upregulated in the cancerous part in the early recurrence group of type C hepatocellular carcinoma cases (38)
- CTH and “AL354872” are genes encoding the same protein.
- genes can be included alone or in appropriate combination in a kit for evaluating cancer.
- Table 16 (to be described later) Can be mentioned.
- the gene may be a partial sequence thereof. These genes can be used as probes for detecting the gene expression described in the table.
- kit of the present invention may include a primer for gene amplification, a buffer, a polymerase and the like.
- the gene amplification primer obtains the DNA sequence and mRNA sequence of each gene sequence from the database, and obtains information including the presence / absence of variants and exon intron structure.
- Target In particular, one primer should be designed so that it spans adjacent exons so that only mRNA is detected.
- a candidate for the design of a primer was obtained. Select a primer that avoids the ring.
- Preferred primers are shown in the general formulas 2n-1 and 2n (n is an integer from 1 to 114).
- the primer represented by 2n-l and the primer represented by 2n can be used as one set.
- n is 1, the primer set of SEQ ID NO: 1 and SEQ ID NO: 2 can be used as one primer set, and if n is 2, the primer set of SEQ ID NO: 3 and SEQ ID NO: 4 can be used. it can.
- Particularly preferred primers are those indicated by n forces 2, 4, 7, 9, and 17.
- hepatocellular carcinoma recurrence inhibitory molecules was advanced at the genetic level using human liver tissues of type B and C hepatocellular carcinoma cases.
- TRIzol regent (Life Technologies, Gaithersburg, MD) was added to the cryopreserved tissue, and homogenized with a polytron. To the homogenate solution was added black-mouthed form, mixed well, and centrifuged. After centrifugation, the upper layer was collected: an equal volume of isopropanol was added, and the total RNA precipitate was collected by centrifugation.
- hepatocellular carcinoma hepatitis B virus caused by hepatitis B virus
- delayed recurrence group of two non-cancerous part and cancer part C type Hepatocellular carcinoma cases (hepatocellular carcinoma with hepatitis C virus as the causative virus) in three groups: non-cancerous part and cancer part in 3 early patients, non-cancerous part and cancer part in 3 recurrence groups Separation and expression analysis were performed.
- RNA transcript labeling kit (Affymetrix, Inc, CA) to synthesize biotin-labeled cRNA.
- genes with a difference of 2.5 times or more between non-cancerous areas with / without recurrence were up34 and down58, and genes with a 3-fold or more difference between cancer areas were up215.
- the number of genes whose expression was increased without recurrence for both type B / C was 0 in non-cancerous parts and 26 in cancerous parts.
- the number of genes whose expression was increased by recurrence for both type B / C was 2 in non-cancerous parts and 3 in cancerous parts.
- there was a gene whose expression was upregulated in both cancerous and non-cancerous parts 5 without recurrence and 10 with recurrence.
- the total in Table 9 is 401, but this is 401 instead of 402 because the overlap of GLUL is special.
- the difference in the prognosis for recurrence is that the gene expression change is greater in the cancerous part than in the non-cancerous part, and the difference in gene expression 4 is greater in ⁇ type hepatocellular carcinoma cases than in type C hepatocellular carcinoma cases.
- Table 1 OA shows the clinicopathological findings and the time to recurrence (the period without recurrence) for each case.
- CH chronic hepatitis
- LC cirrhosis
- the number of months without recurrence is the number of months until recurrence
- CH chronic hepatitis
- LC cirrhosis
- NL normal liver
- the number of months without recurrence is the number of months until recurrence
- Table 2 shows the genes (CNgood) that are upregulated in non-cancer The relationship between the recurrence period and the expression level was examined for a total of 21 genes, including 9 genes and 12 genes (CNbad) whose expression is enhanced in the non-cancerous part of the early recurrence group in Table 6.
- to1 RNA was extracted from the non-cancerous liver tissue of each case in the same manner as in Example 1 above.
- DNase I DNase I (TAKARA SHUZO, Kyoto, Japan) at 37 ° C for 20 minutes, and then repurified with TRIzol regent.
- a reverse transcription reaction was carried out using 100 units of a reaction mixture containing 25 units of AMV reverse transcriptase XL (TAKARA) and 250 pmol of a 9-mer random primer.
- Real-time PCR was performed using 0.25 to 50 ng of each of the synthesized cDNAs.
- ABI PRISM 7000 (Applied Biosystems) was used for preheating at 95 ° C for 10 minutes using a 25 x 1 reaction solution of SYBR Green PCR Master mix (Applied Biosystems, Foster City, CA), and then 15 at 95 PCR was performed under the conditions of 60 ° C (or 65) followed by seconds and 40 to 45 cycles for 60 seconds.
- Relative quantitative analysis was performed using glyceraldehyde 3-phosphatase dehydrogenase (GAPDH) or 18S rRA as the internal standard gene of each sample, and some were subjected to absolute quantitative analysis. Serial dilutions of the standard samples were measured at the same time and used for the calibration curve. The threshold line at which the calibration curve was optimal was determined, and the number of threshold PCR cycles and the threshold cycle (Ct) value of each sample were determined. The A Ct value was calculated by subtracting the Ct value of GAPDH or 18S rRNA from the Ct value of the target gene, and this was used as the relative expression level of the target gene. Furthermore, the value calculated using the formula of 2 ( _A Ct) was used for evaluation of the linear expression level.
- GAPDH glyceraldehyde 3-phosphatase dehydrogenase
- 18S rRA 18S rRA
- the ratio between the delayed recurrence group (case numbers 59, 18, 6) and the early group (case numbers 14, 15, 44) was determined from the results of quantitative PCR of This means that the result was the same as the result of the microarray of Example 1;
- the ratio is preferably 1.5 or more, more preferably 2 or more.
- the number in the box next to “ ⁇ ” indicates the value of the ratio (ratio of the average of three cases).
- An “X” in the “Match microarray” column indicates a discrepancy with the microarray results. “XX” indicates an inverse correlation with the microarray result.
- ⁇ correlation '' refers to the relationship between the gene expression level and the time to recurrence in 22 cases or 31 cases for which the number of months of recurrence has been determined. Means a correlation between the two, and when the correlation is significant, the ⁇ or r value is indicated, and the p value is described.
- Table 11B and Table 12B in the column of “significant difference between the two groups”, 19 cases with recurrence within 24 months and 6 cases without recurrence for more than 40 months (Table 11B and Table 12B Difference), or 4 cases without recurrence for more than 58 months (Table 11B, Table 12B “Significant difference between two groups” column, lower column). The value (Mann-Whitney, U test) is shown.
- the primer sequences (sense strand (order) and antisense strand (reverse)) used in the test are shown in Table 11A, Table 11B, Table 12A and Table 12B (SEQ ID NOS: 1 to 88).
- Table 11A and Table 11B show the results of analysis of nine gene candidates (CNgood) whose expression is upregulated in the non-cancerous part in the recurrence delay group of type C hepatocellular carcinoma cases.
- Table 11A shows the results of quantitative PCR performed on the cases shown in Table 1OA using GAPDH as the internal standard gene under the conditions shown in Table 11A.
- Table 11A Results of quantitative PCR of "genes whose expression is upregulated in non-cancerous areas in the group with delayed recurrence of hepatitis C"
- the ratio of the delayed recurrence group / early group was calculated, and those that were 1.5 or more were marked as ⁇ .
- the correlation is indicated by an O and a p-value is shown for those showing a correlation between the gene expression level of 22 cases and the period until recurrence.
- eight genes were in agreement with the results of the microarray, of which four genes (RALGDS, GBP1, DKFZp564F212, TNFSF10) showed a correlation with the time to recurrence.
- Table 1 IB results of determination of hepatitis that expression is upregulated in non-cancerous areas in the group with delayed recurrence of hepatitis type *
- the expression ⁇ of each gene according to the standard is determined by using as a control gene and the relative value to the expression position.
- the agreement with the microarray was determined by calculating the ratio of the delayed recurrence group / early group from the results of the constant SPCR of the 6 cases used in the microarray analysis.
- Table 12A and Table 12B show the results of analysis of 12 gene traps (CNbad) whose expression is upregulated in non-cancerous areas in the early recurrence group of type C hepatocellular carcinoma cases.
- Table 12A shows the results of quantitative PCR performed on the cases shown in Table 1OA using GAPDH as the internal standard gene under the conditions shown in Table 12A.
- Table 12A ⁇ Genes whose expression is upregulated in non-cancerous areas in the early relapse group of patients with hepatitis C '' Quantitative PGR results
- the QPRT gene was a gene showing an inverse correlation. As a result, seven genes were in agreement with the microarray results, but none of the genes significantly correlated with the time to recurrence. However, the QPRT gene showed a significant inverse correlation. Therefore, this gene was identified as a gene whose expression is upregulated in non-cancerous sites in the recurrence delay group.
- Table 12B shows the results of quantitative PCR performed on the cases shown in Table 10B under the conditions shown in Table 12B using GAPDH or 18S rRNA as the internal standard gene.
- PSMB8 gene also called LMP7 gene: gene for proteasome subunit, beta type, 8
- RALGDS rejection is child: ral guanine nucleotide dissociation stimulator; rito child GBP1 direct transduction na: guanylate-binding protein 1 remains 1s child
- RPS14 gene ribosomal protein S14 gene
- CXCL9 gene gene for chemokine (C-X-C motif) ligand 9
- DKFZp564F212 gene An expressed gene found in the German Genome Project, for which no gene product has been identified and its function has not been predicted.
- CYP1B1 family 1ST cytochrome P450, family 1, subfamily B, polypeptide 1 family,
- TNFSFIO Abbreviation for TNF (ligand) super family, member 10, a ji gene of TNF-related apoptosis inducing ligand (TRAIL)
- NR0B2 1 child nuclear receptor subfamily 0, group B, member 2
- MAFB j3 ⁇ 4fe-f v-maf mus culo ap oneur o tic fibrosarcoma oncogene homolog B gene
- BF530535 gene Gene product whose gene product has not been identified and whose function cannot be predicted
- MRPL24 reprinted copy mitochondrial ribosomal protein L24 gene
- VNNl gene vanin 1 gene
- CH chronic hepatitis
- LC cirrhosis
- NL normal liver.
- stage I / H is unknown though it is either.
- the number of months without recurrence includes the number of months up to recurrence, as well as those without recurrence at the time of the survey.
- the relationship between the recurrence period and the expression level was examined for a total of 71 genes, of which 47 are genes (BNbad) whose expression is enhanced in the non-cancerous part of the early recurrence group in Table 5, and in Table 5.
- RNA was extracted from the non-cancerous liver tissue of each case in the same manner as in Example 1 above.
- the cells were treated with DNase I (DNase I (TAKARA SHUZO, Kyoto, Japan) at 37 ° C for 20 minutes, and then re-purified with TRIzol regent.
- Reverse transcription was performed using 100 units of a reaction solution containing 25 units of AMV reverse transcriptase XL (TAKA A) and 250 pmol of a 9-mer random primer.
- DNase I DNase I (TAKARA SHUZO, Kyoto, Japan)
- TRIzol regent Reverse transcription was performed using 100 units of a reaction solution containing 25 units of AMV reverse transcriptase XL (TAKA A) and 250 pmol of a 9-mer random primer.
- Real-time PCR was performed using 0.25 to 50 ng of each synthesized cDNA.
- ABI PRISM 7000 (Applied Biosystems) was used for preheating for 95 and 10 minutes using 251 reaction solutions of SYBR Green PCR Master mix (Applied Biosystems, Foster City, CA), and then at 95 ° C for 15 seconds. Subsequently, PCR was performed under the conditions of 60 ° C (or at 65) for 60 seconds for 40-45 cycles.
- Absolute quantitative analysis was performed using GAPDH or 18S rRNA as an internal standard gene in each sample. Standard samples were serially diluted and measured at the same time and used for the calibration curve.
- the absolute expression levels of the target gene and the internal standard gene were determined, and the ratio of the target gene expression level to the internal standard gene expression level for each sample was calculated and used for evaluation. All measurements were performed in duplicate.
- “Match with microarray” in Tables 14 and 15 refers to the four cases (case numbers 67, 60, 13, and 9 in Table 13) used in the microarray analysis, as described in Example 2. From the results of the quantitative PCR, the ratio between the delayed recurrence group (Case Nos. 67 and 60) and the early group (Case Nos. 13 and 9) was calculated, and the ratio of 1.5 or more was consistent with the microarray result of Example 1. Means that. A sample having the above ratio of 1.5 or more, preferably 2 or more was rated as ⁇ . The numbers in and adjacent to “ ⁇ ” indicate the value of the ratio. The “X” in the “Match microarray” column indicates a discrepancy with the microarray results. “XX” indicates an inverse correlation with the result of the microarray.
- the “correlation” column in Tables 14 and 15 shows the r-value and p for the correlation between the gene expression level and the period until recurrence in 10 cases for which the number of months of recurrence has been determined. The values are described.
- the primer sequences (sense strand (order), antisense strand (reverse)) used in the test are shown in Tables 14 and 15 (SEQ ID NOS: 89 to 228).
- Table 14 shows the results of analyzing 24 gene candidates (BNgood) whose expression is upregulated in non-cancerous areas in the group with delayed recurrence of type B hepatocellular carcinoma cases.
- Table 14 shows the results of quantitative PCR performed on the cases shown in Table 13 using GAPDH or 18S rNA as the internal standard gene under the conditions shown in Table 14. 5'-3 ') one one ⁇ , ⁇
- the number of genes that matched the results of the microarray was 19 when GAPDH was used as the internal standard gene, of which the phase was equivalent to the time to recurrence There were no genes.
- the number of genes that matched the results of the microarray was 9 when 18srRNA was used as the internal standard gene, and one of them (PZP gene) showed a correlation with the time to recurrence.
- the agreement with the microarray was determined by calculating the ratio of the early recurrence group to the late delay group based on the results of the fixed rack in the example used for the microarray analysis.
- MAP3K5 Regression is: mitogen-activated protein kinase kinase kinase 5 Remission is child TNFSF14 to tocolate: tumor necrosis factor (ligand) superfamily, member 14
- LMNA gene lamin A / C gene
- CYPIAI ⁇ ⁇ cytochrome P450, family 1, subfamily A, polypeptide 1
- IGFBP3 is islet: a gene for insulin-like growth factor binding protein 3
- Example 4
- the expression level of each gene in the VNN1, CXCL9, GBP1, and RALGDS gene sets may be examined. The expression level of each gene is substituted into a discriminant using a discriminant function coefficient obtained for each gene, and the value is used for discrimination.
- the classification rate between the early recurrence group and the late recurrence group is 88% for GAPDH correction and 100% for 18S rRNA.
- the expression level may be determined. If the above discrimination is corrected using 18S rRNA as an internal standard gene, the expression level of each gene in the LMNA, LTBP2, COL1A2, and PZP gene sets may be examined. As described above, these expression levels are substituted into a discriminant, and the values are used for discrimination.
- the classification rate between the early recurrence group and the late recurrence group by analyzing the expression level of the gene group is 100% in both the case of GAPDH correction and the case of 18S rRNA.
- PRODH miKTp Proline dehydrogenase (oxidase) 1
- LTBP2 relapse: latent transrormmg growth factor oeta binding protein 2; mfe child
- COL1A2 gene collagen, type I, alpha 1 gene
- MAP3K12 remains: mitogen-activated protein kinase kinase kinase 12 remains to ⁇
- SEQ ID NOS: 1-28 Synthetic DNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005513492A JPWO2005021745A1 (ja) | 2003-08-22 | 2004-08-23 | 肝細胞癌に関連する遺伝子 |
CA002536324A CA2536324A1 (en) | 2003-08-22 | 2004-08-23 | Hepatocellular cancer-associated gene |
US10/568,533 US20110086342A1 (en) | 2003-08-22 | 2004-08-23 | Hepatocellular Carcinoma-Associated Gene |
EP04772381A EP1661991A4 (en) | 2003-08-24 | 2004-08-23 | WITH HEPATOCELLULAR CARCINOMA ASSOCIATED GEN |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-299363 | 2003-08-22 | ||
JP2003299363 | 2003-08-24 | ||
JP2003334444 | 2003-09-25 | ||
JP2003-334444 | 2003-09-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005021745A1 true WO2005021745A1 (ja) | 2005-03-10 |
WO2005021745A8 WO2005021745A8 (ja) | 2006-04-06 |
Family
ID=34277618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/012425 WO2005021745A1 (ja) | 2003-08-22 | 2004-08-23 | 肝細胞癌に関連する遺伝子 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20110086342A1 (ja) |
JP (1) | JPWO2005021745A1 (ja) |
CA (1) | CA2536324A1 (ja) |
WO (1) | WO2005021745A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007139742A (ja) * | 2005-11-18 | 2007-06-07 | Chi Mei Foundation Medical Center | 肝細胞癌の素因および/または予後を決定するためのバイオマーカー |
JP2008000126A (ja) * | 2006-05-24 | 2008-01-10 | Kanazawa Univ | 遺伝子発現プロファイルによるc型肝硬変及び肝癌の検出 |
EP2363505A3 (en) * | 2007-05-04 | 2011-12-21 | Dermtech International | Diagnosis of melanoma by nucleic acid analysis |
JP5299885B2 (ja) * | 2005-08-12 | 2013-09-25 | 学校法人日本大学 | Hcv陽性肝細胞癌の発癌・再発に関連する遺伝子 |
JP2015008686A (ja) * | 2013-06-28 | 2015-01-19 | 三菱レイヨン株式会社 | 肝臓細胞又はその前駆細胞に由来する細胞の状態を評価する方法、並びに、その方法に用いるプローブ又はプローブセット及びマイクロアレイ |
NO20170739A1 (en) * | 2017-05-04 | 2018-11-05 | Patogen As | Novel virus in Fish and Method for detection |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007058623A1 (en) * | 2005-11-21 | 2007-05-24 | Singapore Health Services Pte Ltd | Methods of predicting hepatocellular carcinoma recurrence by the determination of hepatocellular carcinoma recurrence-associated molecular biomarkers |
FR2910147B1 (fr) * | 2006-12-19 | 2009-02-06 | Galderma Res & Dev S N C Snc | Methode correctrice de traitement de resultats d'experiences transcriptomiques obtenus par analyse differentielle |
JP4858344B2 (ja) * | 2007-07-25 | 2012-01-18 | ソニー株式会社 | 毛を用いた生体リズム情報取得方法 |
WO2011085271A2 (en) | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
KR20120022504A (ko) * | 2010-07-30 | 2012-03-12 | 서울대학교산학협력단 | 간 질환의 진단, 치료 및 예방용 조성물 |
CN105814204B (zh) | 2013-12-24 | 2020-04-28 | Ionis制药公司 | 促血管生成素样3表达的调节 |
-
2004
- 2004-08-23 WO PCT/JP2004/012425 patent/WO2005021745A1/ja active Application Filing
- 2004-08-23 JP JP2005513492A patent/JPWO2005021745A1/ja active Pending
- 2004-08-23 US US10/568,533 patent/US20110086342A1/en not_active Abandoned
- 2004-08-23 CA CA002536324A patent/CA2536324A1/en not_active Abandoned
Non-Patent Citations (8)
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5299885B2 (ja) * | 2005-08-12 | 2013-09-25 | 学校法人日本大学 | Hcv陽性肝細胞癌の発癌・再発に関連する遺伝子 |
JP2007139742A (ja) * | 2005-11-18 | 2007-06-07 | Chi Mei Foundation Medical Center | 肝細胞癌の素因および/または予後を決定するためのバイオマーカー |
JP2008000126A (ja) * | 2006-05-24 | 2008-01-10 | Kanazawa Univ | 遺伝子発現プロファイルによるc型肝硬変及び肝癌の検出 |
EP2363505A3 (en) * | 2007-05-04 | 2011-12-21 | Dermtech International | Diagnosis of melanoma by nucleic acid analysis |
JP2015008686A (ja) * | 2013-06-28 | 2015-01-19 | 三菱レイヨン株式会社 | 肝臓細胞又はその前駆細胞に由来する細胞の状態を評価する方法、並びに、その方法に用いるプローブ又はプローブセット及びマイクロアレイ |
NO20170739A1 (en) * | 2017-05-04 | 2018-11-05 | Patogen As | Novel virus in Fish and Method for detection |
NO344051B1 (en) * | 2017-05-04 | 2019-08-26 | Patogen As | Novel virus in Fish and Method for detection |
Also Published As
Publication number | Publication date |
---|---|
US20110086342A1 (en) | 2011-04-14 |
JPWO2005021745A1 (ja) | 2006-10-26 |
CA2536324A1 (en) | 2005-03-10 |
WO2005021745A8 (ja) | 2006-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Weiss et al. | Revisiting determinants of prognosis in cutaneous melanoma | |
JP5921602B2 (ja) | 患者の癌の進行およびその転帰の生体外予後診断方法、および該方法を実施するための手段 | |
US20030138793A1 (en) | Molecular signatures of commonly fatal carcinomas | |
WO2010064702A1 (ja) | 癌の予後を予測するためのバイオマーカー | |
CA2760333A1 (en) | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy | |
Pass et al. | Biomarkers and molecular testing for early detection, diagnosis, and therapeutic prediction of lung cancer | |
WO2005021745A1 (ja) | 肝細胞癌に関連する遺伝子 | |
US20160222461A1 (en) | Methods and kits for diagnosing the prognosis of cancer patients | |
Yu et al. | Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma | |
Finn et al. | Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy | |
Huang et al. | Molecular gene signature and prognosis of non-small cell lung cancer | |
Chen et al. | cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer | |
KR101847815B1 (ko) | 삼중음성유방암의 아형 분류 방법 | |
KR101200194B1 (ko) | 간암 진단용 마커로서의 socs6의 용도 | |
EP1661991A1 (en) | Hepatocellular cancer-associated gene | |
US20060134622A1 (en) | Amplified cancer target genes useful in diagnosis and thereapeutic screening | |
CN108456730B (zh) | 一种复发风险基因群作为标志物在制备评估乳腺癌分子分型内远处复发风险的产品中的应用 | |
JP5044837B2 (ja) | 食道癌の検出方法 | |
Shi et al. | HLA-DPA1 overexpression inhibits cancer progression, reduces resistance to cisplatin, and correlates with increased immune infiltration in lung adenocarcinoma | |
CN116656811B (zh) | 胰腺导管腺癌预后检测试剂盒及其应用 | |
JP7411979B2 (ja) | 内部標準遺伝子 | |
EP3530758A1 (en) | Method for determining the in vitro presence of a target molecule in a biological sample, and its use for the in vitro analysis of cancers, in particular soft-tissue sarcomas and gastrointestinal stromal tumors | |
Choesmel et al. | Design of a real time quantitative PCR assay to assess global mRNA amplification of small size specimens for microarray hybridisation | |
KR20240065877A (ko) | 공간 전사체 분석 기반의 면역 치료 반응성 예측용 바이오마커 및 이의 용도 | |
Ma et al. | Immune-based prognostic biomarkers associated with metastasis of osteosarcoma. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005513492 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2536324 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004772381 Country of ref document: EP |
|
WR | Later publication of a revised version of an international search report | ||
WWP | Wipo information: published in national office |
Ref document number: 2004772381 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10568533 Country of ref document: US |